The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Stem Cell are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak
Strong
Over the last 90 days Stem Cell Authority has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent basic indicators, Stem Cell is not utilizing all of its potentials. The recent stock price mess, may contribute to short-term losses for the institutional investors. ...more
Stem
Stem Cell Relative Risk vs. Return Landscape
If you would invest 0.01 in Stem Cell Authority on November 25, 2025 and sell it today you would earn a total of 0.00 from holding Stem Cell Authority or generate 0.0% return on investment over 90 days. Stem Cell Authority is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Stem, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Stem Cell Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Stem Cell for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Stem Cell Authority can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Stem Cell Authority generated a negative expected return over the last 90 days
Stem Cell Authority has some characteristics of a very speculative penny stock
Stem Cell Fundamentals Growth
Stem Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Stem Cell, and Stem Cell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Stem Pink Sheet performance.
By examining Stem Cell's fundamental ratios, stakeholders can obtain critical insights into Stem Cell's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Stem Cell is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells. The companys technology enables birthing professionals with a stem cell preservation program to serve their maternity patients in the United States. Stem Cell operates under Medical Care Facilities classification in the United States and is traded on OTC Exchange.
Things to note about Stem Cell Authority performance evaluation
Checking the ongoing alerts about Stem Cell for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Stem Cell Authority help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Stem Cell Authority generated a negative expected return over the last 90 days
Stem Cell Authority has some characteristics of a very speculative penny stock
Evaluating Stem Cell's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Stem Cell's pink sheet performance include:
Analyzing Stem Cell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Stem Cell's stock is overvalued or undervalued compared to its peers.
Examining Stem Cell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Stem Cell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Stem Cell's management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of Stem Cell's pink sheet. These opinions can provide insight into Stem Cell's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Stem Cell's pink sheet performance is not an exact science, and many factors can impact Stem Cell's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Other Information on Investing in Stem Pink Sheet
Stem Cell financial ratios help investors to determine whether Stem Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stem with respect to the benefits of owning Stem Cell security.